Analysis of imp3 expression in prostate adenocarcinomas
Author(s) -
Hülya Tosun Yıldırım,
Nilay Şentürk
Publication year - 2012
Publication title -
turkish journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.305
H-Index - 14
eISSN - 1309-5730
pISSN - 1018-5615
DOI - 10.5146/tjpath.2012.01111
Subject(s) - prostate , medicine , prostate cancer , adenocarcinoma , insulin like growth factor , immunohistochemistry , pca3 , growth factor , oncology , pathogenesis , risk factor , pathology , cancer , receptor
Prostate cancer is the second most common cause of male cancer deaths after lung cancer in developed countries. The prognostic factors currently identified for prostate carcinoma include preoperative serum PSA, TNM staging system, histological grade and surgical margin status and are composed of the clinically most important and useful parameters. However, all the markers studied have not been applied in clinical practice. The oncofetal protein Insulin-Like Growth Factor II has been demonstrated to be associated with aggressive tumor behavior in many organs including urothelial tumors and renal cell carcinoma. Our aim was to investigate the expression status of Insulin-Like Growth Factor II in benign prostate glands, high grade PIN and prostate adenocarcinoma, and to determine the role of Insulin-Like Growth Factor II in pathogenesis of prostate adenocarcinoma.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom